Compare Wahed FTSE USA Shariah ETF (HLAL) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Wahed FTSE USA Shariah ETF vs BIO-TECHNE Corp — how do they compare? Wahed FTSE USA Shariah ETF trades at $72.69, while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: BIO-TECHNE Corp pays a 0.44% dividend while Wahed FTSE USA Shariah ETF pays none. Which is the better fit depends on your goals.
| HLAL | TECH | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $73.60 | $72.29 |
52-Week Low | $55.52 | $43.31 |
Market Cap | — | $11.24B |
Enterprise Value | — | $11.32B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HLAL stock trades at $73.14, up 0.71% with strong bullish technical signals from moving averages. The stock shows positive momentum with key indicators suggesting upward trend continuation. Recent dividend announcement of $0.02 scheduled for June 2026 provides long-term income potential.
The stock presents a bullish technical outlook with fundamental analysis limited by incomplete financial data. Investment opportunity lies in the strong technical momentum, though risks include potential overbought conditions and lack of current financial metrics for comprehensive valuation assessment.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Wahed FTSE USA Shariah ETF
HLAL is an ETF that invests in Shariah-compliant US companies. It follows a rigorous screening process to exclude businesses involved in non-compliant activities like interest-based finance, alcohol, and gambling.
Read more on HLAL →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
